Our Approach: Viral Vectors Made Accessible
We aim to provide cost effective gene therapy treatments to every patient in need and take a patient first approach to industry partnerships.
It starts with the patient
Our goal is to pave the way to clinical success. We start with your indication and dosing strategy to determine the most effective and economical approach to guide your program from discovery to GMP. Leveraging our proprietary platform, your production is tailored to provide the highest quality vectors at exceptional value.
We take a data-driven, no-nonsense approach to your program
Resetting the baseline in CDMO Partnerships
We are committed to the success of our visionary partners. Our personalized approach offers support at every stage of the development journey with keen focus on efficiency and cost-effectiveness. Our simplified, one-stream process enables us to:
Lower Costs
- Platform bridging, no classic process development
- Simplified Production Platform
- Reduced Material Needs
Enhance Quality
- Minimize risk through Platform Robustness
- High vector quantities, up to 1e17 vg total vector genomes, >90% full capsids
- High Purity Vectors, >90% full capsids
Move Faster
- Reduce redundancy
- Supply chain and GMP integration
- No tech transfer activities
- Proven platform
Our platform
Our super-producing AAV platform provides the most vector per dollar without compromise. At its core is a proprietary cell line and transfection method that produces 1E17 total vg, making it applicable to even the most dose-demanding indications.